TheraRadar
← Back
Data updated: Sep 20, 2026

NAVINTA LLC

Generics
ImmunologyOncologyNeurology

NAVINTA LLC is a generic drug manufacturer focused on Immunology, Oncology, Neurology. Key products include SODIUM PHENYLACETATE AND SODIUM BENZOATE.

2008
Since
20
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

NAVINTA LLC's Key Drugs

NAVINTA LLC's core commercial portfolio centers on SODIUM PHENYLACETATE AND SODIUM BENZOATE, spanning Immunology and Oncology — its most strategically important drugs approved in the last 15 years.

SODIUM PHENYLACETATE AND SODIUM BENZOATE
Rare Disease

Hyperammonemia

Approved 2016

NAVINTA LLC's Recent FDA Approvals

NAVINTA LLC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

NAVINTA LLC's Therapeutic Areas

NAVINTA LLC's approved drugs and pipeline span 5 therapeutic areas, led by Immunology and Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 33%
2 drugs
Oncology 17%
1 drugs
Neurology 17%
1 drugs
Infectious Disease 17%
1 drugs
Cardiovascular 17%
1 drugs

NAVINTA LLC Pipeline Snapshot

Active clinical trials for NAVINTA LLC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • SODIUM PHENYLACETATE AND SODIUM BENZOATE leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Immunology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling